المؤلفون: Durán, Carlos E., Riera-Arnau, Judit, Abtahi, Shahab, Pajouheshnia, Romin, Hoxhaj, Vjola, Gamba, Magdalena, Alsina, Ema, Martin-Perez, Mar, Garcia-Poza, Patricia, Llorente-Garcia, Ana, Gonzalez-Bermejo, Diana, Ibánez, Luisa, Sabaté, M. nica, Vidal, Xavier, Ballarín, Elena, Sanfélix-Gimeno, Gabriel, Rodríguez-Bernal, Clara, Peiró, Salvador, García-Sempere, Aníbal, Sanchez-Saez, Francisco, Ientile, Valentina, Ingrasciotta, Ylenia, Guarneri, Claudio, Tanaglia, Matilde, Tari, Michele, Herings, Ron, Houben, Eline, Swart-Polinder, Karin, Holthuis, Emily, Huerta, Consuelo, Gini, Rosa, Roberto, Giuseppe, Bartolini, Claudia, Paoletti, Olga, Limoncella, Giorgio, Girardi, Anna, Hyeraci, Giulia, Andersen, Morten, Kristiansen, Sarah Brøgger, Hallgreen, Christine Erikstrup, Klungel, Olaf, Sturkenboom, Miriam

المصدر: Durán , C E , Riera-Arnau , J , Abtahi , S , Pajouheshnia , R , Hoxhaj , V , Gamba , M , Alsina , E , Martin-Perez , M , Garcia-Poza , P , Llorente-Garcia , A , Gonzalez-Bermejo , D , Ibánez , L , Sabaté , M N , Vidal , X , Ballarín , E , Sanfélix-Gimeno , G , Rodríguez-Bernal , C , Peiró , S , García-Sempere , A , Sanchez-Saez , F , Ientile , V , Ingrasciotta , Y , Guarneri , C , Tanaglia , M , Tari ....

الوصف: Background: In March 2018, the European pregnancy prevention programme for oral retinoids was updated as part of risk minimisation measures (RMM), emphasising their contraindication in pregnant women. Objective: To measure the impact of the 2018 revision of the RMMs in Europe by assessing the utilisation patterns of isotretinoin, alitretinoin and acitretin, contraceptive measures, pregnancy testing, discontinuation, and pregnancy occurrence concomitantly with a retinoid prescription. Methods: An interrupted time series (ITS) analysis to compare level and trend changes after the risk minimisation measures implementation was conducted on a cohort of females of childbearing age (12–55 years of age) from January 2010 to December 2020, derived from six electronic health data sources in four countries: Denmark, Netherlands, Spain, and Italy. Monthly utilisation figures (incidence rates [IR], prevalence rates [PR] and proportions) of oral retinoids were calculated, as well as discontinuation rates, contraception coverage, pregnancy testing, and rates of exposed pregnancies to oral retinoids, before and after the 2018 RMMs. Results: From 10,714,182 females of child-bearing age, 88,992 used an oral retinoid at any point during the study period (mean age 18.9–22.2 years old). We found non-significant level and trend changes in incidence or prevalence of retinoid use in females of child-bearing age after the 2018 RMMs. The reason of discontinuation was unknown in >95% of cases. Contraception use showed a significant increase trend in Spain; for other databases this information was limited. Pregnancy testing was hardly recorded thus was not possible to model ITS analyses. After the 2018 RMM, rates of pregnancy occurrence during retinoid use, and start of a retinoid during a pregnancy varied from 0.0 to 0.4, and from 0.2 to 0.8, respectively. Conclusion: This study shows a limited impact of the 2018 RMMs on oral retinoids utilisation patterns among females of child-bearing age in four European countries. Pregnancies still ...

العلاقة: https://research.vumc.nl/en/publications/4a44efe7-09cf-45c5-96f2-7aa703e4ada8Test

الإتاحة: https://doi.org/10.3389/fphar.2023.1207976Test
https://research.vumc.nl/en/publications/4a44efe7-09cf-45c5-96f2-7aa703e4ada8Test
http://www.scopus.com/inward/record.url?scp=85169601692&partnerID=8YFLogxKTest

المؤلفون: Durán, Carlos E, Riera-Arnau, Judit, Abtahi, Shahab, Pajouheshnia, Romin, Hoxhaj, Vjola, Gamba, Magdalena, Alsina, Ema, Martin-Perez, Mar, Garcia-Poza, Patricia, Llorente-Garcia, Ana, Gonzalez-Bermejo, Diana, Ibánez, Luisa, Sabaté, Mònica, Vidal, Xavier, Ballarín, Elena, Sanfélix-Gimeno, Gabriel, Rodríguez-Bernal, Clara, Peiró, Salvador, García-Sempere, Aníbal, Sanchez-Saez, Francisco, Ientile, Valentina, Ingrasciotta, Ylenia, Guarneri, Claudio, Tanaglia, Matilde, Tari, Michele, Herings, Ron, Houben, Eline, Swart-Polinder, Karin, Holthuis, Emily, Huerta, Consuelo, Gini, Rosa, Roberto, Giuseppe, Bartolini, Claudia, Paoletti, Olga, Limoncella, Giorgio, Girardi, Anna, Hyeraci, Giulia, Andersen, Morten, Kristiansen, Sarah Brøgger, Hallgreen, Christine Erikstrup, Klungel, Olaf, Sturkenboom, Miriam

المساهمون: RWE/Causal inference, Epi Infectieziekten Team 2, Data Science & Biostatistiek, Child Health

مصطلحات موضوعية: acne, contraceptive measures, dermatologic conditions, isotretinoin, oral retinoids, pregnancy prevention programme, risk minimisation measures, Pharmacology (medical), Pharmacology

الوصف: Background: In March 2018, the European pregnancy prevention programme for oral retinoids was updated as part of risk minimisation measures (RMM), emphasising their contraindication in pregnant women. Objective: To measure the impact of the 2018 revision of the RMMs in Europe by assessing the utilisation patterns of isotretinoin, alitretinoin and acitretin, contraceptive measures, pregnancy testing, discontinuation, and pregnancy occurrence concomitantly with a retinoid prescription. Methods: An interrupted time series (ITS) analysis to compare level and trend changes after the risk minimisation measures implementation was conducted on a cohort of females of childbearing age (12-55 years of age) from January 2010 to December 2020, derived from six electronic health data sources in four countries: Denmark, Netherlands, Spain, and Italy. Monthly utilisation figures (incidence rates [IR], prevalence rates [PR] and proportions) of oral retinoids were calculated, as well as discontinuation rates, contraception coverage, pregnancy testing, and rates of exposed pregnancies to oral retinoids, before and after the 2018 RMMs. Results: From 10,714,182 females of child-bearing age, 88,992 used an oral retinoid at any point during the study period (mean age 18.9-22.2 years old). We found non-significant level and trend changes in incidence or prevalence of retinoid use in females of child-bearing age after the 2018 RMMs. The reason of discontinuation was unknown in >95% of cases. Contraception use showed a significant increase trend in Spain; for other databases this information was limited. Pregnancy testing was hardly recorded thus was not possible to model ITS analyses. After the 2018 RMM, rates of pregnancy occurrence during retinoid use, and start of a retinoid during a pregnancy varied from 0.0 to 0.4, and from 0.2 to 0.8, respectively. Conclusion: This study shows a limited impact of the 2018 RMMs on oral retinoids utilisation patterns among females of child-bearing age in four European countries. Pregnancies still ...

وصف الملف: application/pdf

العلاقة: https://dspace.library.uu.nl/handle/1874/450312Test

الإتاحة: https://dspace.library.uu.nl/handle/1874/450312Test

المؤلفون: Kitchin, Álvaro, Huerta Álvarez, Consuelo, Llorente García, Ana, Martínez Hernández, David, Ortega Molina, Paloma, Cea Soriano, Lucía

مصطلحات موضوعية: antidepressants, anxiolytics, case control study, exposure, miscarriage, Ginecología y obstetricia, Salud pública (Medicina), 3201.08 Ginecología, 3212 Salud Pública

الوصف: CRUE-CSIC (Acuerdos Transformativos 2022) ; Purpose: Despite the notable increase on the prescription of antidepressants and anxiolytics during pregnancy, recommendation on maintaining the treatment during prenatal period is still controversial. We aimed to separately assess the role of effects of the antidepressants and anxiolytic and the underlying illness, controlled by potential confounding associated with miscarriage onset. Methods: We used data from a validated pregnant cohort aged 15–49 years from 2002 to 2016 using BIFAP database. All confirmed miscarriages were used to perform a nested control analysis using conditional logistic regression. Women were classified according to use of each drug of interest into four mutually exclusive groups: nonusers, users only during prepregnancy, continuers, and initiators during first trimester. Adjusted odds ratios (aORs) for major confounders during pregnancy such as number of visits to primary care practitioners visits, obesity, smoking, HTA, diabetes with 95% confidence intervals were calculated. Results: Compared with nonusers, antidepressants continuers had the highest increased risk of miscarriage aOR (95%) of 1.29 (1.13–1.46), being continuers of paroxetine and fluoxetine the antidepressants with the strongest association. Likewise, continuers of anxiolytics and initiators showed an increased risk of 1.19 (1.04–1.37) and 1.30 (1.13–1.50). When separating the effect between the condition itself or the treatment, women exposed during first trimester, regardless treatment duration and/or the underlying illness, had the highest risk 1.27 (1.08–1.51) for antidepressants and 1.25 (1.13–1.39) for anxiolytics. Conclusions: Our analysis showed an association between prenatal exposure to antidepressants and anxiolytics and miscarriage onset after controlling by potential confounding adjusting for confounders and the underlying illness. This association was not supported for hypnotic medications. Further studies are warranted to evaluate the risk of miscarriage among ...

وصف الملف: application/pdf

العلاقة: https://doi.org/10.1002/pds.5488Test; https://hdl.handle.net/20.500.14352/71712Test

الإتاحة: https://doi.org/20.500.14352/71712Test
https://doi.org/10.1002/pds.5488Test
https://hdl.handle.net/20.500.14352/71712Test

المؤلفون: Reyes, Carlen, León-Muñoz, Luz M., Pistillo, Andrea, Jóhannesdóttir Schmidt, Sigrún Alba, Kristensen, Kasper Bruun, Puente, Diana, LLorente-García, Ana, Huerta-Álvarez, Consuelo, Pottegård, Anton, Duarte-Salles, Talita

المصدر: Reyes , C , León-Muñoz , L M , Pistillo , A , Jóhannesdóttir Schmidt , S A , Kristensen , K B , Puente , D , LLorente-García , A , Huerta-Álvarez , C , Pottegård , A & Duarte-Salles , T 2022 , ' Flecainide and risk of skin neoplasms : Results of a large nested case–control study in Spain and Denmark ' , Frontiers in Pharmacology , vol. 13 , 1002451 . https://doi.org/10.3389/fphar.2022.1002451Test

مصطلحات موضوعية: case-control studies, database, flecainide, melanoma, skin neoplasm

الوصف: Background: A previous study in Denmark suggested an increased melanoma risk associated with the use of flecainide. Objective: To study the association between flecainide use and the risk of melanoma and non-melanoma skin cancer in Spain and Denmark. Methods: We conducted a multi-database case–control study in (database/study period) Spain (SIDIAP/2005–2017 and BIFAP/2007–2017) and Denmark (Danish registries/2001–2018). We included incident cases of melanoma or non-melanoma skin cancer (NMSC) aged ≥18 with ≥2 years of previous data (≥10 years for Denmark) before the skin cancer and matched them to controls (10:1 by age and sex). We excluded persons with immunosuppression or previous cancer. We defined ever-use as any prescription fill and high-use as a cumulative dose of at least 200 g (reference: never-use). We categorized a cumulative dose for a dose–response assessment. We used conditional logistic regression to compute ORs (95% CI) adjusted for photosensitizing, anti-neoplastic, disease-specific drugs and comorbidities. Results: The total numbers of melanoma/NMSC cases included were 7,809/64,230 in SIDIAP, 4,661/31,063 in BIFAP, and 27,978/152,821 in Denmark. In Denmark, high-use of flecainide was associated with increased adjusted ORs of skin cancer compared with never-use [melanoma: OR 1.97 (1.38–2.81); NMSC: OR 1.34 (1.15–1.56)]. In Spain, an association between high-use of flecainide and NMSC was also observed [BIFAP: OR 1.42 (1.04–1.93); SIDIAP: OR 1.19 (0.95–1.48)]. There was a non-significant dose–response pattern for melanoma in Denmark and no apparent dose–response pattern for NMSC in any of the three databases. We found similar results for ever-use of flecainide. Conclusion: Flecainide use was associated with an increased risk of melanoma (Denmark only) and NMSC (Denmark and Spain) but without substantial evidence of dose–response patterns. Further studies are needed to assess for possible unmeasured confounders.

العلاقة: https://pure.au.dk/portal/da/publications/flecainide-and-risk-of-skin-neoplasmsTest(e40b9738-0b1f-4593-acfa-479f19c64840).html

الإتاحة: https://doi.org/10.3389/fphar.2022.1002451Test
https://pure.au.dk/portal/da/publications/flecainide-and-risk-of-skin-neoplasmsTest(e40b9738-0b1f-4593-acfa-479f19c64840).html

المؤلفون: BRAEYE, Toon, Emborg, Hanne-Dorthe, Llorente-Garcia, Ana, Huerta, Consuelo, Martin-Merino, Elisa, Duarte-Salles, Talita, Danieli, Giorgia, Tramontan, Lara, Weibel, Daniel, McGee, Chris, Villa, Marco, Gini, Rosa, Lehtinen, Matti, Titievsky, Lina, Sturkenboom, Miriam

المساهمون: BRAEYE, Toon, Emborg, Hanne-Dorthe, Llorente-Garcia, Ana, Huerta, Consuelo, Martin-Merino, Elisa, Duarte-Salles, Talita, Danieli, Giorgia, Tramontan, Lara, Weibel, Daniel, McGee, Chris, Villa, Marco, Gini, Rosa, Lehtinen, Matti, Titievsky, Lina, Sturkenboom, Miriam

المصدر: Article

مصطلحات موضوعية: Vaccination coverage, Influenza vaccines, Papillomavirus vaccines, Measles vaccines, Probability

الوصف: Background: The Accelerated Development of VAccine beNefit-risk Collaboration in Europe (ADVANCE) is a public-private collaboration aiming to develop and test a system for rapid benefit-risk monitoring of vaccines using existing healthcare databases in Europe. We estimated vaccine coverage from electronic healthcare databases as part of a fit-for-purpose assessment for vaccine benefit-risk studies. Methods: A retrospective dynamic cohort study was conducted through a distributed network approach. Coverage with measles-vaccine for birth year 2006, human papillomavirus (HPV)-vaccine for birth years 1990-2000 and influenza-vaccine for birth years 1920-1950 was estimated using period-prevalence and inverse probability weighting methods. Seven databases from four countries participated: Italy (Pedianet, Val Padana), Spain (BIFAP, SIDIAP), UK (RCGP-RSC, THIN), Denmark (SSI/AUH). Database access providers extracted the data, transformed it into a common structure and ran an R-script locally. The created output tables were shared and pooled at a central server. Results: The total study population comprised 274,616 persons for measles-vaccine, 2,011,666 persons for HPV-vaccine and 14,904,033 persons for influenza-vaccine. Measles-vaccine coverage varied from 84.3% (Denmark) to 96.5% (Italy, Val Padana) for the first dose and from 82.8% (Italy, Val Padana) to 90.9% (UK) for the second dose at the age of 7 years. The HPV-vaccine coverage, aggregated over birth years 1997-2000, ranged from 60% (UK) to 88.3% (Denmark) at the age of 15 years. The influenza-vaccine coverage for the influenza seasons from 2009 to 2015 for persons aged 65 years and more was roughly stable around 43% in Denmark and around 68% in the UK while a decrease from 58 to 50% was observed in Catalonia (Spain). Conclusions: We obtained detailed, age-specific coverage estimates though a common procedure. We discussed between database comparability and comparability to published national estimates. ; The Innovative Medicines Initiative Joint Undertaking ...

وصف الملف: application/pdf

العلاقة: VACCINE, 38 (16) , p. 3243 -3254; http://hdl.handle.net/1942/31187Test; 3254; 16; 3243; 38; WOS:000525317600011

الإتاحة: https://doi.org/10.1016/j.vaccine.2020.02.082Test
http://hdl.handle.net/1942/31187Test

المؤلفون: Leon-Munoz, Luz M., Duarte-Salles, Talita, Llorente-Garcia, Ana, Diaz-Rodriguez, Yesika, Pottegard, Anton, Montero-Corominas, Dolores, Huerta-Alvarez, Consuelo

المصدر: Leon-Munoz , L M , Duarte-Salles , T , Llorente-Garcia , A , Diaz-Rodriguez , Y , Pottegard , A , Montero-Corominas , D & Huerta-Alvarez , C 2020 , ' Use of hydrochlorothiazide and risk of skin cancer in a large nested case-control study in Spain ' , Pharmacoepidemiology and Drug Safety , vol. 29 , no. Suppl. 3 , 4711 , pp. 573 . < https://doi.org/10.1002/pds.5114Test >

الإتاحة: https://doi.org/10.1002/pds.5114Test
https://portal.findresearcher.sdu.dk/da/publications/d5bfbad2-d754-48dc-9c51-00a00916e449Test

المؤلفون: Antón-Juanilla, Marta, Navarro-Martínez, Adela, Llorente-García, Ana Isabel, Prieto-Millán, Sergio Martín, Bouchier-Hayes, David

المصدر: European Urology Open Science ; volume 31, page S4-S5 ; ISSN 2666-1683

مصطلحات موضوعية: Urology

الإتاحة: https://doi.org/10.1016/s2666-1683Test(21)00169-5
https://api.elsevier.com/content/article/PII:S2666168321001695?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S2666168321001695?httpAccept=text/plainTest

المؤلفون: Martín-Merino, Elisa, Llorente-García, Ana, Montero Corominas, Dolores, Huerta-Álvarez, Consuelo

المصدر: Pharmaceutical Medicine ; volume 33, issue 4, page 367-367 ; ISSN 1178-2595 1179-1993

مصطلحات موضوعية: Pharmacology (medical), Pharmacology

الإتاحة: https://doi.org/10.1007/s40290-019-00293-0Test

المؤلفون: Martín-Merino, Elisa, Calderón-Larrañaga, Amaia, Hawley, Samuel, Poblador-Plou, Beatriz, Llorente-García, Ana, Petersen, Irene, Prieto-Alhambra, Daniel

المصدر: Clinical Epidemiology ; volume Volume 10, page 643-654 ; ISSN 1179-1349

الإتاحة: https://doi.org/10.2147/clep.s154914Test
https://www.dovepress.com/getfile.php?fileID=42452Test

المؤلفون: Castillo-Cano, Belén, Martín-Pérez, Mar, Llorente-García, Ana, Montero-Corominas, Dolores, Comas-Cufí, Marc, Martín-Merino, Elisa

المصدر: Vaccine ; volume 40, issue 33, page 4816-4826 ; ISSN 0264-410X

مصطلحات موضوعية: Infectious Diseases, Public Health, Environmental and Occupational Health, General Veterinary, General Immunology and Microbiology, Molecular Medicine

الإتاحة: https://doi.org/10.1016/j.vaccine.2022.06.060Test
https://api.elsevier.com/content/article/PII:S0264410X22008295?httpAccept=text/xmlTest
https://api.elsevier.com/content/article/PII:S0264410X22008295?httpAccept=text/plainTest